Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients.
about
Assessing bleeding risk in patients taking anticoagulantsEvidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesNeuraxial and peripheral nerve blocks in patients taking anticoagulant or thromboprophylactic drugs: challenges and solutionsA systematic review of validated methods for identifying atrial fibrillation using administrative dataIntracerebral haemorrhage: an often neglected medical emergencyOcular bleeding related to warfarin anticoagulation in patients with mechanical heart valve and atrial fibrillationPolypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolismFactors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studiesEarly and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'.Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review.Impact of Triple Therapy in Elderly Patients with Atrial Fibrillation Undergoing Percutaneous Coronary InterventionPreventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants.Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists.Interruption to antiplatelet therapy early after acute ischaemic stroke: a nested case-control study.Proposal for the Rapid Reversal of Coagulopathy in Patients with Nonoperative Head Injuries on Anticoagulants and/or Antiplatelet Agents: A Case Study and Literature Review.Adenosine A2A receptor agonists with potent antiplatelet activity.Stroke prevention with oral anticoagulation in older people with atrial fibrillation - a pragmatic approach.Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation.Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherenceThe Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial FibrillationContemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies.Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'.Inappropriate combination of warfarin and aspirinAre the risk factors listed in warfarin prescribing information associated with anticoagulation-related bleeding? A systematic literature review.Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants.Bleeding risk prediction models in atrial fibrillation.Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta-analysis.Brain endothelial cell specific integrins and ischemic stroke.Cardiovascular Safety and Bleeding Risk Associated with Nonsteroidal Anti-Inflammatory Medications in Patients with Cardiovascular Disease.Antithrombotic treatment in atrial fibrillation.Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers.Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs.Percent Time With a Supratherapeutic INR in Atrial Fibrillation Patients Also Using an Antiplatelet Agent Is Associated With Long-Term Risk of Dementia.Risk factors for atrial fibrillation and their population burden in postmenopausal women: the Women's Health Initiative Observational Study.Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality.Resumption of Anticoagulation After Intracranial Hemorrhage.Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study.Hemorrhage after ischemic stroke - relation to age and previous hemorrhage in a nationwide cohort of 58,868 patients.
P2860
Q24619070-57D3551B-32B6-498A-8623-2890F9D38A9FQ24632951-CC7E9A40-D775-431F-BE43-F7B0E964D939Q26782931-2755B743-7D25-47B2-A4D3-2249F6C5853BQ27026830-F1C92402-3773-4456-B3B0-B608C77DC263Q28212587-9FA38A7F-B781-4012-8AAB-B6E005E1A772Q28222062-006FB070-193E-41D6-B8BB-86CB422F46CCQ33417203-CAFDF580-37A0-4C20-A65E-0F5FA03A870CQ34388959-E2828948-FB39-4F19-A112-E1E15F155AD5Q34585334-E86BD047-8815-4550-A32E-4AF6701CE6B9Q34609020-412D1ECE-CDE1-46DB-9603-9E3816A82A6DQ35016262-584C3B83-8767-4D4F-AC86-8AC915338E36Q35903857-EE4EB48B-DB99-43C0-894F-486AEB5F0D28Q35938914-327654A5-865A-4E79-AD8D-F0F52F2E32A8Q36217536-6FC52164-910C-4F74-88CF-7BF9518BB96AQ36310002-735EC1C2-8F14-492F-9354-86879469413AQ36331578-EC57A3A0-2912-449B-AA24-A44E0F575EDBQ36371663-1EFD11BF-9CBA-4FD7-A242-6844E0B34CAEQ36409072-0B93EA10-032C-49B9-8986-D1417FFB1BCFQ36496846-9E850624-E40D-4F59-BC9B-F9C4E9B61D7DQ36551541-B16B07B7-738E-4432-8EAF-7C331715A4D5Q36847664-ACC0ED5B-0A36-46DB-8CD4-1608BA60BD92Q37246263-59F5ECF7-D758-45BF-9733-BA811223CE0AQ37251490-4000126F-A71A-4D73-853E-914F03A865C0Q37521378-1564E96B-1608-4FD1-9F13-B92F27251130Q37680357-F3E043BE-5735-4CB7-8EAD-6295754F3331Q37890023-FA6F8022-9661-413B-B707-A8E238843714Q38087193-0C4BB83D-93EB-4675-A602-EC597E5D7C4EQ38165077-E054B0EE-7A64-4F0B-93F6-77749B2ADAEFQ38224507-C8F30F45-5F16-44B2-B21E-A11DEA589EF9Q38254946-95A891E6-13CA-469F-8DEE-F37D892A27E3Q38990657-A390DCF5-87AF-4068-9A00-7AA70E1D7C8BQ41878910-472873B6-3FDA-4D1C-8311-7C382A77D76CQ43247664-83C1FB41-5D4E-4BB6-B011-4DB22F425040Q44461490-20B46C5A-056D-4693-8995-FEE85D6A444FQ45140840-DF5BFBC2-8A47-49BC-B6A1-FF243D2432CFQ46918663-20D58FEB-7F8C-4742-910F-45EE48E41274Q47838584-D5328A23-E647-4F4A-9A4F-01AD11BAB24AQ47891553-0D249F18-208C-4D99-A02F-A8FC83866BC2Q47938006-DDB598FB-D611-47DA-B8DE-33227CA8B25EQ48783012-BB3B957C-2902-4EE2-B1DC-F28EBAA27506
P2860
Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Combined anticoagulant-antipla ...... atrial fibrillation patients.
@en
Combined anticoagulant-antipla ...... atrial fibrillation patients.
@nl
type
label
Combined anticoagulant-antipla ...... atrial fibrillation patients.
@en
Combined anticoagulant-antipla ...... atrial fibrillation patients.
@nl
prefLabel
Combined anticoagulant-antipla ...... atrial fibrillation patients.
@en
Combined anticoagulant-antipla ...... atrial fibrillation patients.
@nl
P921
P1433
P1476
Combined anticoagulant-antipla ...... y atrial fibrillation patients
@en
P2093
Patricia A Howard
Theresa I Shireman
P304
P356
10.1161/01.STR.0000141933.75462.C2
P407
P577
2004-08-26T00:00:00Z